Skip to main content

Table 3 Multivariate Cox-regression model

From: Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

  Progression-free survival (PFS) Overall survival (OS)
HR (95% CI) p Value HR (95% CI) p Value
Age ≤ 35 1.16 (0.81–1.66) 0.431 1.21 (0.76–1.93) 0.425
ECOG ≥1 1.55 (1.10–2.16) 0.011 1.51 (0.96–2.36) 0.074
Visceral metastasis 1.27 (0.91–1.78) 0.156 1.25 (0.79–2.00) 0.344
PgR-negative 1.61 (0.99–2.62) 0.056 1.56 (0.85–2.85) 0.152
Initial endocrine therapy 0.59 (0.41–0.88) 0.009 0.73 (0.43–1.22) 0.224
Chemotherapy-endocrine therapy 0.34 (0.21–0.55) < 0.001 0.40 (0.20–0.78) 0.007
  1. HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PgR progesterone receptor. All treatments were begun prior to disease progression